Phase 3
Completed N=28
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Source: ClinicalTrials.gov NCT02665273 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Achieve Freedom From Headache |
4; 0 | — |
| SECONDARY Sustained Headache Relief |
3; 0 | — |
| SECONDARY Would Want the Same Treatment Again During a Subsequent Migraine |
5; 3 | — |
Eligibility Criteria
Inclusion Criteria
- ED patient with acute migraine or probable migraine
- Fail first line therapy with metoclopramide
Exclusion Criteria
- Can't obtain consent
- Concern for secondary headache
- Skull defect
- Propensity for bleeding
- Overlying infection
- Pregnancy
- Allergy, intolerance study medication
Data sourced from ClinicalTrials.gov (NCT02665273). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.